Voyager Therapeutics, Inc. (VYGR) Insider Bernard Ravina Sells 5,490 Shares

Voyager Therapeutics, Inc. (NASDAQ:VYGR) insider Bernard Ravina sold 5,490 shares of the company’s stock in a transaction on Friday, November 10th. The stock was sold at an average price of $13.26, for a total transaction of $72,797.40. Following the sale, the insider now directly owns 16,473 shares of the company’s stock, valued at $218,431.98. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Bernard Ravina also recently made the following trade(s):

  • On Tuesday, October 10th, Bernard Ravina sold 10,980 shares of Voyager Therapeutics stock. The stock was sold at an average price of $20.33, for a total transaction of $223,223.40.
  • On Monday, September 11th, Bernard Ravina sold 16,470 shares of Voyager Therapeutics stock. The stock was sold at an average price of $12.87, for a total transaction of $211,968.90.
  • On Tuesday, September 5th, Bernard Ravina sold 5,490 shares of Voyager Therapeutics stock. The stock was sold at an average price of $10.00, for a total transaction of $54,900.00.

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) opened at $12.26 on Tuesday. Voyager Therapeutics, Inc. has a 12 month low of $8.10 and a 12 month high of $25.99.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://transcriptdaily.com/2017/11/14/voyager-therapeutics-inc-vygr-insider-bernard-ravina-sells-5490-shares.html.

VYGR has been the topic of a number of recent analyst reports. Stifel Nicolaus reiterated a “buy” rating and issued a $31.00 price objective (up previously from $20.00) on shares of Voyager Therapeutics in a report on Monday, October 23rd. Canaccord Genuity initiated coverage on shares of Voyager Therapeutics in a report on Friday, October 27th. They issued a “buy” rating and a $35.00 price objective on the stock. Zacks Investment Research lowered shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. ValuEngine upgraded shares of Voyager Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Finally, Raymond James Financial, Inc. initiated coverage on shares of Voyager Therapeutics in a report on Thursday, October 12th. They issued an “outperform” rating and a $35.00 price objective on the stock. Three analysts have rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $27.88.

Several institutional investors have recently modified their holdings of VYGR. Wells Fargo & Company MN raised its stake in shares of Voyager Therapeutics by 312.8% in the 3rd quarter. Wells Fargo & Company MN now owns 377,190 shares of the company’s stock valued at $7,766,000 after purchasing an additional 285,806 shares in the last quarter. Citadel Advisors LLC acquired a new stake in shares of Voyager Therapeutics in the 3rd quarter valued at about $5,155,000. DAFNA Capital Management LLC raised its stake in shares of Voyager Therapeutics by 187.2% in the 2nd quarter. DAFNA Capital Management LLC now owns 204,808 shares of the company’s stock valued at $1,835,000 after purchasing an additional 133,488 shares in the last quarter. Mckinley Capital Management LLC Delaware acquired a new stake in shares of Voyager Therapeutics in the 3rd quarter valued at about $1,412,000. Finally, Dimensional Fund Advisors LP raised its stake in shares of Voyager Therapeutics by 232.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 98,128 shares of the company’s stock valued at $879,000 after purchasing an additional 68,574 shares in the last quarter. Institutional investors and hedge funds own 40.93% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply